Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508784 | 1.00 | BTK (0.49) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL471719 | 1.00 | BTK (0.49) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL21617625 | 0.93 | BTK (0.43) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL470791 | 0.91 | BTK (0.53) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL458573 | 0.88 | BTK (0.51) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL18498476 | 0.86 | BTK (0.51) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL28110628 | 0.82 | MAPT (0.47) | KMT2AEPHX1 | |
| SCHEMBL1498382 | 0.81 | BTK (0.53) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL25223172 | 0.79 | BTK (0.55) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL28611976 | 0.79 | BTK (0.55) | BTKCTSKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120247755-A | JM01 purifying preparation method | 山东大医精诚药业有限公司 | 2025-07-04 | — | — | CN | disclosed |
| EP-3299356-B1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-11-24 | — | — | EP | disclosed |
| EP-3299356-B1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-11-24 | — | — | EP | disclosed |
| CN-111662220-A | Pleuromutilin compounds for treating novel bacterial infectious diseases secondary to coronavirus pneumonia | 常州安蒂卫生物科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-111170911-A | Pleuromutilin compounds for treating bacterial infectious diseases | 安帝康（无锡）生物科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3299356-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2018-03-28 | — | — | EP | disclosed |
| EP-3299356-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2018-03-28 | — | — | EP | disclosed |
| EP-3052473-B1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATE FOR THE PREPARATION OF OSELTAMIVIR PHOSPHATE | COUNCIL SCIENT IND RES (IN) | 2018-01-17 | — | — | EP | disclosed |
| EP-2576505-B1 | CRYSTALLINE FORM OF A PLEUROMUTILIN | NABRIVA THERAPEUTICS AG (AT) | 2017-11-29 | — | — | EP | disclosed |
| EP-2576505-B1 | CRYSTALLINE FORM OF A PLEUROMUTILIN | NABRIVA THERAPEUTICS AG (AT) | 2017-11-29 | — | — | EP | disclosed |
| US-20130079400-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-03-28 | — | — | US | disclosed |
| US-20130079400-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-03-28 | — | — | US | disclosed |
| US-20130079400-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-03-28 | — | — | US | disclosed |
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2013-03-21 | — | — | US | disclosed |
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2013-03-21 | — | — | US | disclosed |
| EP-2399904-A1 | Process for the preparation of pleuromutilins | Nabriva Therapeutics AG (AT) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011146953-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146954-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146953-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2011-12-01 | — | — | WO | disclosed |
| EP-2390245-A1 | Enantiomerically pure amines | Nabriva Therapeutics AG (AT) | 2011-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | PTMA, QPCTL, ATIC | BTK 4476/4885CTSK 4227/4885NFKB1 1942/4885 |
| US-20130079400-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, SSRP1 | BTK 4461/4885CTSK 4200/4885NFKB1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.